Faster, cheaper, better? Post-buyout deal Celgene jumps into AI alliance with a $25 million bet on speeding discovery work
Celgene clearly isn’t waiting in limbo to see when, or if, the big Bristol-Myers Squibb deal will go through. It’s still executing deals, and the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
